PE20211550A1 - Pamoato de ketamina y su uso - Google Patents

Pamoato de ketamina y su uso

Info

Publication number
PE20211550A1
PE20211550A1 PE2021000756A PE2021000756A PE20211550A1 PE 20211550 A1 PE20211550 A1 PE 20211550A1 PE 2021000756 A PE2021000756 A PE 2021000756A PE 2021000756 A PE2021000756 A PE 2021000756A PE 20211550 A1 PE20211550 A1 PE 20211550A1
Authority
PE
Peru
Prior art keywords
pamoate
ketamine
salts
ketamine pamoate
anesthetic
Prior art date
Application number
PE2021000756A
Other languages
English (en)
Inventor
Tong-Ho Lin
Yung-Shun Wen
Chia-Hsien Chen
Wei-Ju Chang
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of PE20211550A1 publication Critical patent/PE20211550A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings

Abstract

Se proporcionan sales de pamoato de ketamina que tienen una estequiometria de 2:1 de ketamina a pamoato, incluyendo pamoato de R, S-ketamina, pamoato de S-ketamina, o pamoato de R-ketamina, y formas cristalinas o amorfas de las sales de pamoato, y que tienen excelente seguridad y propiedades para aplicaciones farmaceuticas. Tambien se proporcionan composiciones farmaceuticas que incluyen las sales de pamoato de la ketamina y sus usos en el tratamiento de una enfermedad del SNC o como anestesico.
PE2021000756A 2019-01-11 2020-01-10 Pamoato de ketamina y su uso PE20211550A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791058P 2019-01-11 2019-01-11
US201962871763P 2019-07-09 2019-07-09
PCT/CN2020/071404 WO2020143762A1 (en) 2019-01-11 2020-01-10 Ketamine pamoate and use thereof

Publications (1)

Publication Number Publication Date
PE20211550A1 true PE20211550A1 (es) 2021-08-16

Family

ID=71521952

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000756A PE20211550A1 (es) 2019-01-11 2020-01-10 Pamoato de ketamina y su uso

Country Status (21)

Country Link
EP (1) EP3908570B1 (es)
JP (1) JP7451538B2 (es)
KR (1) KR20210116517A (es)
CN (1) CN113423686B (es)
AU (1) AU2020206826B2 (es)
BR (1) BR112021013340A2 (es)
CA (1) CA3118954A1 (es)
CL (1) CL2021001803A1 (es)
CO (1) CO2021006884A2 (es)
DK (1) DK3908570T3 (es)
FI (1) FI3908570T3 (es)
LT (1) LT3908570T (es)
MX (1) MX2021006029A (es)
PE (1) PE20211550A1 (es)
PH (1) PH12021551157A1 (es)
PT (1) PT3908570T (es)
RS (1) RS65271B1 (es)
SG (1) SG11202104792SA (es)
SI (1) SI3908570T1 (es)
TW (1) TWI827783B (es)
WO (1) WO2020143762A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076410A4 (en) * 2019-12-20 2024-02-07 Alar Pharmaceuticals Inc LONG-ACTING INJECTABLE FORMULATIONS OF KETAMINE PAMOATE SALTS
CN112263572A (zh) * 2020-11-17 2021-01-26 厦门大学附属翔安医院 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US9421266B2 (en) * 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
JO2857B1 (en) 2008-06-16 2015-03-15 سانوفي أفينتس Vinyl pipers with modified activity of tumor-resistant TNF
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JP2014196292A (ja) 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
AU2017242867B9 (en) 2016-03-29 2019-07-04 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Vortioxetine pamoic acid salt and crystal form thereof
CN110325179A (zh) * 2016-12-26 2019-10-11 塞尔利克斯生物私人有限公司 用于治疗慢性疼痛的组合物和方法

Also Published As

Publication number Publication date
EP3908570A4 (en) 2022-10-19
PT3908570T (pt) 2024-03-15
DK3908570T3 (da) 2024-02-26
JP2022518003A (ja) 2022-03-11
CO2021006884A2 (es) 2021-06-10
BR112021013340A2 (pt) 2021-09-14
AU2020206826B2 (en) 2024-05-02
TWI827783B (zh) 2024-01-01
CN113423686A (zh) 2021-09-21
EP3908570A1 (en) 2021-11-17
LT3908570T (lt) 2024-03-12
PH12021551157A1 (en) 2021-11-03
EP3908570B1 (en) 2023-12-13
KR20210116517A (ko) 2021-09-27
CA3118954A1 (en) 2020-07-16
JP7451538B2 (ja) 2024-03-18
SI3908570T1 (sl) 2024-04-30
US20220119338A1 (en) 2022-04-21
TW202042796A (zh) 2020-12-01
WO2020143762A1 (en) 2020-07-16
FI3908570T3 (fi) 2024-02-13
SG11202104792SA (en) 2021-06-29
RS65271B1 (sr) 2024-03-29
CN113423686B (zh) 2023-08-22
CL2021001803A1 (es) 2021-12-24
AU2020206826A1 (en) 2021-06-03
MX2021006029A (es) 2021-09-23

Similar Documents

Publication Publication Date Title
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2018002060A2 (es) Compuestos farmacéuticos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112018009281A8 (pt) composições para tratar atrofia muscular espinhal
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
DOP2011000218A (es) Derivados de sulfonamida
CO6690805A2 (es) 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3
CL2021001803A1 (es) Pamoato de ketamina y su uso
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina